Ono Pharmaceutical (https://www.ono.co.jp/eng/) announced the establishment of the new Immune-mediated Inflammatory Diseases Consortium for Drug Development to run drug discovery research targeting immune-mediated inflammatory diseases. Other participants to the initiative include Keio University, Kochi University, National Institutes of Biomedical Innovation, Health and Nutrition, Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo. The consortium will work to overcome challenges due to limitations on clinical samples from immune-mediated inflammatory diseases and further increases in research costs.

LEAVE A REPLY

Please enter your comment!
Please enter your name here